NHS
Pan Mersey
Area Prescribing Committee

DENOSUMAB solution for injection (Prolia®) for bone loss associated with long-term systemic glucocorticoid therapy

The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of DENOSUMAB solution for injection (Prolia®) for bone loss associated with long-term systemic glucocorticoid therapy.

GREY

Denosumab is licensed for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.[1]

This recommendation will be reviewed if a formal application for use is received and prioritised for in-year review.

In the meantime, clinicians should continue to follow national guidance for managing bone loss associated with long-term systemic glucocorticoid therapy:

- NICE Pathway: Osteoporosis (last updated 04 November 2020)
- NICE Clinical Knowledge Summaries (CKS): Osteoporosis – prevention of fragility fractures (last updated May 2020)

Please refer to the Pan Mersey APC Prescribing Support Information: Denosumab 60mg in 1ml prefilled syringe for Pan Mersey APC approved uses of denosumab (Prolia®).

References

1. Amgen Ltd. Summary of Product Characteristics; Prolia 60 mg solution for injection in pre-filled syringe, September 2020. Accessed online 15 April 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.